Barclays
BTTX

Barclays’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Barclays’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-232
Closed -$251 – 4751
2023
Q2 		$251 Buy
+232
New +$224 ﹤0.01% 4413

Other funds holding BTTX

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Barclays's BTTX Position: Q3 2023 in Review

Barclays sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q3 2023, closing a stake of 232 shares — an estimated $251 sold.

Barclays first reported a position in BTTX in Q2 2023 and held it in 1 quarter. The position peaked at $251 in Q2 2023. 18 funds tracked by Wall St. Rank hold BTTX as of Q3 2023.

  • Barclays reported no remaining Better Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Barclays sold 232 Better Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $251.
  • Barclays first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Barclays's Better Therapeutics, Inc. Common Stock position peaked at $251 in Q2 2023.
  • 18 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.